Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease

Sarah Appleton, Terry Jones, Phillippa Poole, Louis Pilotto, Robert Adams, Toby J. Lasserson, Brian J Smith, Julia Muhammad

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This review looks at studies that compare the regular use for at least four weeks of different types of inhaled short‐acting bronchodilator medication in people with chronic obstructive pulmonary disease (COPD, or emphysema/chronic bronchitis). There were eleven trials included. There were no major differences seen between the responses to ipratropium and salbutamol, or the combination. Where there were benefits, they were small and would not support a general recommendation for the use of ipratropium bromide or a combination with beta‐2 agonist over a beta‐2 agonist alone in COPD. People with COPD could use the short‐acting bronchodilator that gives them the most improvement in their symptoms.
Original languageEnglish
Article numberCD001387
JournalCochrane Database of Systematic Reviews
Volume2006
Issue number2
DOIs
Publication statusPublished - 19 Apr 2006

Keywords

  • Chronic obstructive pulmonary disease
  • bronchodilators
  • long term therapy

Fingerprint Dive into the research topics of 'Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Cite this